IP Library Granted Patent US 7,807,780
Granted Patent B2
US 7,807,780 · App. 09/910,432 · Granted Oct 5, 2010

Multi-component biological transport systems

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,807,780
App. No.
09/910,432
Granted
Oct 5, 2010
Kind
B2
Abstract

Compositions and methods are provided that are useful for the delivery of therapeutic agents, including nucleic acids. The compositions can be prepared with components useful for targeting the delivery of the compositions as well as imaging components.

Claims (10)

1. A composition comprising a non-covalent association complex of:

a positively charged backbone covalently attached to a plurality of amino acid sequences, wherein said amino acid sequences are selected from the group consisting of (gly) p -RGRDDRRQRRR-(gly) q (SEQ ID NO:19), and (gly) p -YGRKKRRQRRR-(gly) q (SEQ ID NO: 20) wherein p and q are each independently an integer of from 0 to 20;

a negatively charged backbone having a plurality of attached targeting agents;

a negatively charged backbone having a plurality of attached biological agents, wherein each of said biological agents is a therapeutic agent or a cosmeceutical agent selected from the group consisting of VEGF, botulinum toxin, EGF, TGF-b1, insulin, a blocker of VEGF, and antibodies to VEGF; and

wherein said non-covalent association complex carries a net positive charge.

2. The composition according to claim 1 , wherein said amino acid sequences have the formula (gly) p -RGRDDRRQRRR-(gly) q (SEQ ID NO:19), wherein p and q are each independently an integer from 0 to 20, and wherein each of said amino acid sequences is attached to said positively charged backbone via the C-terminus or the N-terminus of said each amino acid sequence.

3. The composition in accordance with claim 2 , wherein the subscripts p and q are each independently integers of from 0 to 8.

4. The composition in accordance with claim 3 , wherein the subscripts p and q are each independently integers of from 2 to 5.

5. The composition according to claim 2 , wherein therapeutic agent is botulinum toxin.

6. The composition according to claim 1 , wherein the biological agent is a therapeutic agent.

Assignments (6)
RELEASE OF SECURITY INTEREST Recorded Sep 27, 2019
From: HERCULES CAPITAL, INC. (F/K/A HERCULES TECHNOLOGY GROWTH CAPITAL, INC.)
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 050565/0300 →
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 24432/321, 24432/284, 24432/317, 22432/187, AND 22756/549 Recorded Oct 4, 2011
From: LEADER VENTURES, LLC
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 027015/0658 →
SECURITY AGREEMENT Recorded Sep 22, 2011
From: REVANCE THERAPEUTICS, INC.
To: HERCULES TECHNOLOGY GROWTH CAPITAL, INC.
Reel/Frame 026953/0726 →
SECURITY AGREEMENT Recorded May 29, 2009
From: REVANCE THERAPEUTICS, INC.
To: LEADER VENTURES, LLC
Reel/Frame 022756/0549 →
CHANGE OF NAME Recorded Mar 20, 2009
From: ESSENTIA BIOSYSTEMS, INC.
To: REVANCE THERAPEUTICS, INC.
Reel/Frame 022431/0053 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 14, 2002
From: WAUGH, JACOB; DAKE, MICHAEL
To: ESSENTIA BIOSYSTEMS, INC.
Reel/Frame 012492/0919 →